Herniated nucleus pulposus (HNP) is one of peripheral neuropathic pain. Although concensus guidelines for the treatment of neuropathic pain are based on the results of the RCT studies, there are still gaps in the literatures. This study aimed to compare the effectiveness and quality of life of gabapentin and amitriptyline for the treatment of pain in HNP. The method used a quasi experimental with consequtive sampling. This study included 30 patients in the gabapentin group and 26 patients in the amitriptyline group, and each group was evaluated for 1 month. Effectiveness was assessed using Visual Analogue Scale (VAS) every 2 weeks then analized by independent and paired sample t test. The results showed that the use of gabapentin and amitriptilin in 4 weeks showed the decrease of pain score measured by visual analog scale 3.70 ± 0.349 and 3.500 ± 0.34 although there was no statistical difference (p value = 0.704). To sum up, effectiveness of gabapentin and amitriptyline in the treatment of neuropathic pain did not have statistical difference.

Pain is often experienced by patients treated in the hospital and is the most frequently reported events in post-surgical patients. Ketorolac associated with the incidence of adverse reactions include, the incidence of acute renal failure and bleeding disorders. The purpose of the study was to observe and report on the profile of adverse reactions include the use of ketorolac on renal function and hemostasis as well as the effectiveness of the analgesic ketorolac. A total of 20 patients who received ketorolac compared to the value of the glomerular filtration rate (GFR), bleeding time (BT), Blood Clotting Time (CT), prothrombin time (PT) and International Normalized Ratio (INR) between before and after patients received ketorolac. Compared to the value of the Visual Analog Scale (VAS) ranging V day I to day administration of ketorolac. One of 20 patients (5%) who use ketorolac for 5 days had decreased GFR by 66.70%.. Whereas for hemostasis testing showed that ketorolac can influence hemostatic seen from increasing on BT (0,04; p <0,05), CT (0,02; p <0,05), PT value (0,03, p <0,05), as well as an increase in INR value (0,03; p <0:05) but still in normal range. Comparison of the mean VAS score from day one to day five showed that administration of ketorolac can reduce pain and disappeared on day 4, where VAS values between days 4 and 5 showed no statistical difference (0,56; p> 0,05). Conclusion. incidence of renal damage incident occurred at 5%, and may affect hemostatic function in patients. Resolution of pain may occur at day 4 ketorolac administration.

Pain is often experienced by patients treated in the hospital and is the most frequently reported events in post-surgical patients. Ketorolac associated with the incidence of adverse reactions include, the incidence of acute renal failure and bleeding disorders. The purpose of the study was to observe and report on the profile of adverse reactions include the use of ketorolac on renal function and hemostasis as well as the effectiveness of the analgesic ketorolac. A total of 20 patients who received ketorolac compared to the value of the glomerular filtration rate (GFR), bleeding time (BT), Blood Clotting Time (CT), prothrombin time (PT) and International Normalized Ratio (INR) between before and after patients received ketorolac. Compared to the value of the Visual Analog Scale (VAS) ranging V day I to day administration of ketorolac. One of 20 patients (5%) who use ketorolac for 5 days had decreased GFR by 66.70%.. Whereas for hemostasis testing showed that ketorolac can influence hemostatic seen from increasing on BT (0,04; p <0,05), CT (0,02; p <0,05), PT value (0,03, p <0,05), as well as an increase in INR value (0,03; p <0:05) but still in normal range. Comparison of the mean VAS score from day one to day five showed that administration of ketorolac can reduce pain and disappeared on day 4, where VAS values between days 4 and 5 showed no statistical difference (0,56; p> 0,05). Conclusion. incidence of renal damage incident occurred at 5%, and may affect hemostatic function in patients. Resolution of pain may occur at day 4 ketorolac administration.